» Articles » PMID: 34267889

Published Randomized Controlled Trials of Surveillance in Cancer Patients - a Systematic Review

Overview
Journal Oncol Rev
Specialty Oncology
Date 2021 Jul 16
PMID 34267889
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

With solid tumor cancer survivorship increasing, the number of patients requiring post-treatment surveillance also continues to increase. This highlights the need for evidence-based cancer surveillance guidelines. Ideally, these guidelines would be based on combined high-quality data from randomized controlled trials (RCTs). We present a systematic review of published cancer surveillance RCTs in which we sought to determine the feasibility of data pooling for guideline development. We carried out a systematic search of medical databases for RCTs in which adult patients with solid tumors that had undergone surgical resection with curative intent and had no metastatic disease at presentation, were randomized to different surveillance regimens that assessed effectiveness on overall survival (OS). We extracted study characteristics and primary and secondary outcomes, and assessed risk of bias and validity of evidence with standardized checklist tools. Our search yielded 32,216 articles for review and 18 distinct RCTs were included in the systematic review. The 18 trials resulted in 23 comparisons of surveillance regimens. There was a highlevel of variation between RCTs, including the study populations evaluated, interventions assessed and follow-up periods for the primary outcome. Most studies evaluated colorectal cancer patients (11/18, [61%]). The risk of bias and validity of evidence were variable and inconsistent across studies. This review demonstrated that there is tremendous heterogeneity among RCTs that evaluate effectiveness of different postoperative surveillance regimens in cancer patients, rendering the consolidation of data to inform high-quality cancer surveillance guidelines unfeasible. Future RCTs in the field should focus on consistent methodology and primary outcome definition.

Citing Articles

Emerging perspectives: unraveling the anticancer potential of vitamin D.

Wakle K, Mokale S, Sakle N Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):2877-2933.

PMID: 37994947 DOI: 10.1007/s00210-023-02819-5.

References
1.
Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A . Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum. 1998; 41(9):1127-33. DOI: 10.1007/BF02239434. View

2.
Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

3.
Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X . Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2005; 24(3):386-93. DOI: 10.1200/JCO.2005.02.0826. View

4.
Primrose J, Perera R, Gray A, Rose P, Fuller A, Corkhill A . Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014; 311(3):263-70. DOI: 10.1001/jama.2013.285718. View

5.
Longo C, Deber R, Fitch M, Williams A, DSouza D . An examination of cancer patients' monthly 'out-of-pocket' costs in Ontario, Canada. Eur J Cancer Care (Engl). 2007; 16(6):500-7. DOI: 10.1111/j.1365-2354.2007.00783.x. View